Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted agents have significantly improved outcomes for metastatic renal cell carcinoma (mRCC).
• The ideal duration of targeted therapy for mRCC remains unclear.
• Disease stabilization and tumor response are common with targeted agents.

Purpose of the Study:

• To review treatment durations with first-line targeted agents for mRCC.
• To identify reasons for treatment discontinuation or switching.
• To discuss strategies for optimizing treatment duration via adverse event management.

Main Methods:

• Literature review of targeted agents approved for first-line mRCC treatment.
• Analysis of treatment durations and reasons for therapy changes.
• Discussion of adverse event management strategies.

Main Results:

• Varied treatment durations observed with approved first-line targeted agents.
• Tumor response, disease stabilization, and adverse events influence treatment decisions.
• Rapid progression through treatment options can occur due to switching.

Conclusions:

• Optimal treatment duration for targeted agents in mRCC requires further investigation.
• Effective adverse event management is key to achieving optimal treatment duration.
• Strategies for managing side effects can help prolong therapy and improve patient outcomes.